Best Practice & Research Clinical Haematology

Papers
(The median citation count of Best Practice & Research Clinical Haematology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Contemporary and future strategies in polycythemia vera47
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation26
The role of randomized controlled trials, registries, observational databases in evaluating new interventions21
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)19
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL17
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes17
Endpoint selection and evaluation in hematology studies16
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program16
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances16
Coagulopathy in COVID-19 and anticoagulation clinical trials15
Editorial Board14
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms14
The presentation of results from studies in clinical haematology14
Advances in CAR design14
Take a spin: Apheresis in the care of adult leukaemia patients14
Blood coagulation and cancer genes13
Accelerated and blast phase myeloproliferative neoplasms13
Vaccine-induced immune thrombotic thrombocytopenia12
Creating a GMP cell processing program: A focus on quality and regulation11
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults10
GATA2 and marrow failure10
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma10
Targeted cellular therapy for treatment of relapsed or refractory leukemia10
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”9
Bone marrow transplantation for acquired aplastic anemia: What's new9
Principles of cost-effectiveness studies and their use in haematology9
The international cooperative Gaucher group (ICCG) Gaucher registry9
Cancer associated thrombosis in pediatric patients9
What should be done and what should be avoided when comparing two treatments?8
Dysregulation of Protein S in COVID-198
The role of registries in hematological disorders8
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?7
Editorial Board7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration7
Addressing symptom burden in myeloproliferative neoplasms7
Clinical experience of CAR T cells for multiple myeloma6
Anti-GM-CSF autoantibodies in myeloid leukemias6
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?6
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation6
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment5
Thrombosis and bleeding in hematological malignancy5
Cytokines in hematopoietic cell transplantation and related cellular therapies5
Advances in polycythemia vera and lessons for acute leukemia5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia5
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies5
Thrombopoietin receptor agonists for marrow failure: A concise clinical review5
CAR assembly line: Taking CAR T-cell manufacturing to the next level5
A reflection on Arnold Caplan, the father of MSC5
Handling missing covariate data in clinical studies in haematology5
Challenges in anticoagulation for patients with brain tumors5
Recent progress in acute leukemia and myelodysplasia5
What is the role of the bone marrow microenvironment in AML?5
Editorial Board / Aims & Scope5
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]4
What is relative survival and what is its role in haematology?4
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation4
The most frequent HLA alleles around the world: A fundamental synopsis4
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia4
Preface4
Cytogenetics and genomics in CML and other myeloproliferative neoplasms4
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]4
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-193
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care3
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma3
When to use which molecular prognostic scoring system in the management of patients with MDS?3
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents3
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation3
Clinical experience of CAR T cell therapy in lymphomas3
Donor lymphocyte infusion in Acute Myeloid Leukemia3
Marrow failure and aging: The role of “Inflammaging”3
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults3
Considerations to comprehensive care for the older individual with myelofibrosis3
Preface of special edition “Biostatistics in clinical haematology”3
CARs for lymphoma3
Bone marrow failure syndromes2
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions2
COVID-19 and antiphospholipid antibodies2
Is there an optimal adjunct therapy to traditional cytotoxic induction?2
Using real-world evidence in haematology2
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy2
Since everyone has a donor, why are some eligible patients still not transplanted?2
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation2
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders2
Cytokine therapy of acute radiation syndrome2
Editorial Board / Aims & Scope2
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?2
Editorial Board / Aims & Scope2
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation1
Graft versus Leukemia in 20231
Allogeneic hematopoietic cell transplantation in acute myeloid leukemia1
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia1
WHO, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice1
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia1
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia1
COVID-19: A hematological perspective1
The best GVHD prophylaxis: Or at least progress towards finding it1
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults1
Transplantation algorithm for myelofibrosis in 2022 and beyond1
New targets for CAR T therapy in hematologic malignancies1
Analyte heterogeneity analysis as a possible potency parameter for MSC1
Clonal hematopoiesis and bone marrow failure syndromes1
Cytogenetics in haematology1
Distinguishing constitutional from acquired bone marrow failure in the hematology clinic1
Editorial Board / Aims & Scope1
Editorial Board1
Redox stress in COVID-19: Implications for hematologic disorders1
Thromboprophylaxis of cancer patients undergoing systemic therapy in the ambulatory setting1
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?1
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry1
Congenital amegakaryocytic thrombocytopenia – Not a single disease1
Editorial Board1
Progress and challenges in the acute leukemia field1
Cytogenetics and genomics of acute myeloid leukemia1
How can we intervene to mitigate post-transplantation relapse in AML? Strategies to mitigate post-transplantation relapse in AML1
Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?1
Myeloproliferative neoplasms in adolescents and young adults1
Cytogenetics and genomics in pediatric acute lymphoblastic leukaemia1
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)1
Designing and conducting a clinical trial in blood and marrow transplantation1
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia1
Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?1
The history of cytokines and growth factors development1
0.21577000617981